Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/12/31 10:58:25」(JST)

wiki en

Bone marrow suppression or myelotoxicity (adjective myelotoxic) or myelosuppression is the decrease in production of cells responsible for providing immunity (leukocytes), carrying oxygen (erythrocytes), and/or those responsible for normal blood clotting (thrombocytes).^[1] Bone marrow suppression is a serious side effect of chemotherapy and certain drugs affecting the immune system such as azathioprine.^[2] The risk is especially high in cytotoxic chemotherapy for leukemia.

Non-steroidal anti-inflammatory drugs, in some rare instances, may also cause bone marrow suppression. The decrease in blood cell counts does not occur right at the start of chemotherapy because the drugs do not destroy the cells already in the bloodstream (these are not dividing rapidly). Instead, the drugs affect new blood cells that are being made by the bone marrow.^[3] When myelosuppression is severe, it is called myeloablation.^[4]

Because the bone marrow is the manufacturing center of blood cells, the suppression of bone marrow activity causes a deficiency of blood cells. This condition can rapidly lead to life-threatening infection, as the body cannot produce leukocytes in response to invading bacteria and viruses, as well as leading to anaemia due to a lack of red blood cells and spontaneous severe bleeding due to deficiency of platelets.

Parvovirus B19 inhibits erythropoiesis by lytically infecting RBC precursors in the bone marrow and is associated with a number of different diseases ranging from benign to severe. In immunocompromised patients, B19 infection may persist for months, leading to chronic anemia with B19 viremia due to chronic marrow suppression.^[5]

Thiazide diuretics can also lead to bone marrow suppression as an adverse effect.

Treatment

Bone marrow suppression due to azathioprine can be treated by changing to another medication such as mycophenolate mofetil (for organ transplants) or other disease-modifying drugs in rheumatoid arthritis or Crohn's disease.

Chemotherapy induced myelosuppression

Bone marrow suppression due to anti-cancer chemotherapy is much harder to treat and often involves hospital admission, strict infection control, and aggressive use of intravenous antibiotics at the first sign of infection.^{[citation needed]}

G-CSF is used clinically (see Neutropenia) but tests in mice suggest it may lead to bone loss.^[6]^[7]

GM-CSF has been compared to G-CSF as a treatment of chemotherapy-induced myelosuppression/Neutropenia.^[8]

Prediction

In developing new chemotherapeutics, the efficacy of the drug against the disease is often balanced against the likely level of myelotoxicity the drug will cause. In-vitro colony forming cell (CFC) assays using normal human bone marrow grown in appropriate semi-solid media such as ColonyGEL have been shown to be useful in predicting the level of clinical myelotoxicity a certain compound might cause if administered to humans.^[9] These predictive in-vitro assays reveal effects the administered compounds have on the bone marrow progenitor cells that produce the various mature cells in the blood and can be used to test the effects of single drugs or the effects of drugs administered in combination with others.

References

^ "bone marrow suppression". Retrieved 3 May 2011.
^ Azathioprine side effects Archived November 25, 2010, at the Wayback Machine.
^ Bone marrow suppression
^ Dictionary of Cancer Terms: myelosuppression
^ Parvovirus B19 - BASICS
^ "Researchers urge monitoring of bone health during chemotherapy".
^ Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K (April 2007). "Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner". Blood. 109 (8): 3424–31. doi:10.1182/blood-2006-09-048686. PMC 1852257. PMID 17192391.
^ Beveridge RA, Miller JA, Kales AN, et al. (1998). "A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression". Cancer Invest. 16 (6): 366–373. doi:10.3109/07357909809115775. PMID 9679526.
^ predicting-drug-induced-myelotoxicity

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 再生不良性貧血：病因、臨床症状および診断 aplastic anemia pathogenesis clinical manifestations and diagnosis
2. 早期乳癌に対する補助化学療法の急性副作用 acute side effects of adjuvant chemotherapy for early stage breast cancer
3. 薬剤誘発性の好中球減少および無顆粒球症 drug induced neutropenia and agranulocytosis
4. 小児および思春期におけるホジキンリンパ腫の概要 overview of hodgkin lymphoma in children and adolescents
5. 成人における抗癌剤の投与 dosing of anticancer agents in adults

English Journal

Approaches to synthetic platelet analogs.

Modery-Pawlowski CL, Tian LL, Pan V, McCrae KR, Mitragotri S, Sen Gupta A.SourceCase Western Reserve University, Department of Biomedical Engineering, Cleveland, OH 44106, USA.
Biomaterials.Biomaterials.2013 Jan;34(2):526-41. doi: 10.1016/j.biomaterials.2012.09.074. Epub 2012 Oct 23.
Platelet transfusion is routinely used for treating bleeding complications in patients with hematologic or oncologic clotting disorders, chemo/radiotherapy-induced myelosuppression, trauma and surgery. Currently, these transfusions mostly use allogeneic platelet concentrates, while products like lyo
PMID 23092864

Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit.

Hou JK, Kramer JR, Richardson P, Sansgiry S, El-Serag HB.SourceHouston VA HSR&D Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Alimentary pharmacology & therapeutics.Aliment Pharmacol Ther.2012 Dec;36(11-12):1049-56. doi: 10.1111/apt.12075. Epub 2012 Oct 14.
BACKGROUND: Immunomodulator medications (IMM) play a vital role in the care of patients with inflammatory bowel disease (IBD). IBD practice guidelines recommend myelosuppression monitoring after initiation of IMM.AIM: To identify adherence rates and predictors of myelosuppression monitoring after IM
PMID 23061548